161 related articles for article (PubMed ID: 26980172)
1. [Hepatic toxicity in HER-2(+) breast cancer patient under treatment with capecitabine and lapatinib].
Romero Carreño E; Marcos Rodríguez JA; Santana Martínez S; de la Cruz Merino L
Farm Hosp; 2016 Mar; 40(2):134-6. PubMed ID: 26980172
[No Abstract] [Full Text] [Related]
2. The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: A systematic review and pooled analysis.
Petrelli F; Ghidini M; Lonati V; Tomasello G; Borgonovo K; Ghilardi M; Cabiddu M; Barni S
Eur J Cancer; 2017 Oct; 84():141-148. PubMed ID: 28810186
[TBL] [Abstract][Full Text] [Related]
3. Lapatinib plus capecitabine resolved human epidermal growth factor receptor 2-positive brain metastases.
Glück S; Castrellon A
Am J Ther; 2009; 16(6):585-90. PubMed ID: 19287304
[TBL] [Abstract][Full Text] [Related]
4. Severe drug-induced thrombocytopenia after treatment with trastuzumab but not with lapatinib.
Cathomas R; von Moos R
Ann Oncol; 2009 Sep; 20(9):1606-1607. PubMed ID: 19622591
[No Abstract] [Full Text] [Related]
5. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.
Gajria D; Gonzalez J; Feigin K; Patil S; Chen C; Theodoulou M; Drullinsky P; D'Andrea G; Lake D; Norton L; Hudis CA; Traina TA
Breast Cancer Res Treat; 2012 Jan; 131(1):111-6. PubMed ID: 21898114
[TBL] [Abstract][Full Text] [Related]
6. Reversible slurred speech related to capecitabine and lapatinib combination in patients with breast cancer.
Mutlu H; Büyükçelik A; Akça Z; Erden A
J Oncol Pharm Pract; 2015 Feb; 21(1):72-3. PubMed ID: 24154651
[TBL] [Abstract][Full Text] [Related]
7. Eruptive nevi in a patient with metastatic breast cancer.
Calleja-Algarra A; Aragón-Miguel R; Velasco-Tamariz V; Andrés-Lencina JJ; Prieto Barrios M; Maroñas Jiménez L; Ortiz Romero PL; Monsálvez Honrubia V
Int J Dermatol; 2017 Dec; 56(12):1508-1509. PubMed ID: 28960262
[No Abstract] [Full Text] [Related]
8. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
[TBL] [Abstract][Full Text] [Related]
9. Prospective validation of HLA-DRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury.
Schaid DJ; Spraggs CF; McDonnell SK; Parham LR; Cox CJ; Ejlertsen B; Finkelstein DM; Rappold E; Curran J; Cardon LR; Goss PE
J Clin Oncol; 2014 Aug; 32(22):2296-303. PubMed ID: 24687830
[TBL] [Abstract][Full Text] [Related]
10. Lapatinib: an oral dual tyrosine kinase inhibitor for HER-2-positive breast cancer.
Sardesai SD; Storniolo AM
Womens Health (Lond); 2015 Jun; 11(3):281-94. PubMed ID: 26102468
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine-induced Subacute Cutaneous Lupus Erythematosus.
Rocha A; Almeida HL; Zerwes G; Oliveira Filho UL
An Bras Dermatol; 2019; 94(5):618-619. PubMed ID: 31777367
[No Abstract] [Full Text] [Related]
12. Antiangiogenic therapy in patients with HER2-positive metastatic breast cancer: a case series.
Le Saux O; You B; Freyer G
Clin Breast Cancer; 2014 Jun; 14(3):e89-94. PubMed ID: 24424314
[No Abstract] [Full Text] [Related]
13. Lapatinib-associated toxicity and practical management recommendations.
Moy B; Goss PE
Oncologist; 2007 Jul; 12(7):756-65. PubMed ID: 17673607
[TBL] [Abstract][Full Text] [Related]
14. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
15. Lapatinib in metastatic breast cancer.
Frenel JS; Bourbouloux E; Berton-Rigaud D; Sadot-Lebouvier S; Zanetti A; Campone M
Womens Health (Lond); 2009 Nov; 5(6):603-12. PubMed ID: 19863462
[TBL] [Abstract][Full Text] [Related]
16. Does toxicity predict efficacy? Insight into the mechanism of action of lapatinib.
Fontanella C; Lederer B; Nekljudova V; Untch M; von Minckwitz G; Loibl S
J Clin Oncol; 2014 Oct; 32(30):3458-9. PubMed ID: 25225430
[No Abstract] [Full Text] [Related]
17. A case of capecitabine-induced hyperpigmentation and radiation recall phenomenon.
Ghosal N; Misra V
Clin Oncol (R Coll Radiol); 2009 Oct; 21(8):632. PubMed ID: 19304468
[No Abstract] [Full Text] [Related]
18. Lapatinib for the treatment of HER2-overexpressing breast cancer.
Jones J; Takeda A; Picot J; von Keyserlingk C; Clegg A
Health Technol Assess; 2009 Oct; 13 Suppl 3():1-6. PubMed ID: 19846022
[TBL] [Abstract][Full Text] [Related]
19. Lapatinib in the treatment of HER-2 overexpressing breast cancer.
Vrdoljak E; Boban M; Ban M
J BUON; 2011; 16(3):393-9. PubMed ID: 22006739
[TBL] [Abstract][Full Text] [Related]
20. TYMS Gene Polymorphisms in Breast Cancer Patients Receiving 5-Fluorouracil-Based Chemotherapy.
Chao YL; Anders CK
Clin Breast Cancer; 2018 Jun; 18(3):e301-e304. PubMed ID: 28899623
[No Abstract] [Full Text] [Related]
[Next] [New Search]
